No Data
No Data
Institutional Investors Must Be Pleased After a 8.9% Gain Last Week That Adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) One-year Returns
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%
Investing in stocks inevitably means buying into some companies that perform poorly. But long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders have had a particularly rough ride in the last
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Ark's Cathie Wood Blasts Big Tech. She Prefers Palantir and These Other Stocks.
Cathie Wood's flagship ARK Innovation exchange-traded fund is 72% below its peak while the S&P 500 is hitting all-time highs.
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.